





Use the same in vivo platform to counter-screen structurally diverse compound libraries against selected neurotoxic exposures and prioritize hits that reduce adverse behavioral effects, with confirmation across doses and additional agents.
High-throughput screening of structurally diverse compound libraries with prioritized hits on week-scale timelines, supporting rapid iteration and rescreening as new agents come into scope.


High-throughput, physiology-relevant discovery increases the probability of finding viable countermeasures and de-risks downstream validation by starting from a whole-organism signal.


